2025
Real-Life Performance of Automated Insulin Delivery Systems for High-Carbohydrate Meals: Are All Systems the Same?
Zanfardino A, Ippolito G, Ozen G, Galderisi A, Rollato A, Chianese A, Testa V, del Giudice E, Scaramuzza A, Iafusco D. Real-Life Performance of Automated Insulin Delivery Systems for High-Carbohydrate Meals: Are All Systems the Same? Diabetes Technology & Therapeutics 2025, 27: 669-673. PMID: 40170658, DOI: 10.1089/dia.2025.0106.Peer-Reviewed Original ResearchHigh-carbohydrate mealInsulin deliveryPostprandial blood glucose levelsType 1 diabetesControl-IQBlood glucose levelsPostprandial glycemic responseNo significant differenceBolus strategyGlycemic controlGlucose levelsAutomated Insulin DeliverySignificant differenceBolusGlycemic responseInsulin bolusMiniMed 780GCorrection bolusesTarget rangeHigh-carbohydratePizza consumptionDelivery systemInsulin delivery systemsAdvancing Telemedicine Using Smart Insulin Pens with Continuous Glucose Monitoring and Telecommunication Systems: A Case Series
Singh L, Gothong C, Ash G, Hernandez R, Spanakis E. Advancing Telemedicine Using Smart Insulin Pens with Continuous Glucose Monitoring and Telecommunication Systems: A Case Series. Journal Of Clinical Medicine 2025, 14: 1794. PMID: 40142601, PMCID: PMC11943169, DOI: 10.3390/jcm14061794.Peer-Reviewed Original ResearchCare deliveryModels of care deliveryDiabetes self-care behaviorsMethods of care deliveryImprove patient engagementSelf-care behaviorsMultiple daily injectionsSelf-management capabilitiesPatient engagementInsulin pensTelecommunication modalitiesVisual educational toolComprehensive telemedicine systemManagement of glycemic controlDietary educationAdvanced telemedicineCase seriesTelemedicine systemType 1 diabetes mellitusEducational toolTelemedicineUncontrolled T1DMGlucose dataGlycemic controlDiabetesPolygenic Susceptibility to Diabetes and Poor Glycemic Control in Stroke Survivors
Demarais Z, Conlon C, Rivier C, Clocchiatti-Tuozzo S, Renedo D, Torres-Lopez V, Sheth K, Meeker D, Zhao H, Ohno-Machado L, Acosta J, Huo S, Falcone G. Polygenic Susceptibility to Diabetes and Poor Glycemic Control in Stroke Survivors. Neurology 2025, 104: e210276. PMID: 39889253, DOI: 10.1212/wnl.0000000000210276.Peer-Reviewed Original ResearchConceptsStroke survivorsWorse glycemic controlPoor glycemic controlStroke patientsAssociated with worse glycemic controlGlycemic controlPolygenic risk scoresClinical management of stroke patientsAssociated with poor glycemic controlManagement of stroke patientsCross-sectional designGenetic association studiesUncontrolled diabetesSusceptibility to T2DMUK BiobankType 2 diabetes mellitusAdverse vascular outcomesRisk scoreAssociation studiesHemoglobin A1cSurvivorsVascular outcomesSusceptibility to diabetesStrokeDiabetes
2024
A systematic review of the use of GLP-1 receptor agonists in surgery
Ihnat J, De Baun H, Carrillo G, Dony A, Mukherjee T, Ayyala H. A systematic review of the use of GLP-1 receptor agonists in surgery. The American Journal Of Surgery 2024, 240: 116119. PMID: 39615284, DOI: 10.1016/j.amjsurg.2024.116119.Peer-Reviewed Original ResearchGLP-1 receptor agonistsGLP-1RAsReceptor agonistsGLP-1Screen preoperative patientsRate of hypoglycemic eventsPotential surgical complicationsDelayed gastric emptyingGLP-1RA useAssociated with improved glycemic controlSystematic reviewNon-bariatric surgeonsSurgical complicationsPeri-operativeGLP-1RABMI thresholdsPre-operativelyPreoperative patientsInsulin useGlycemic controlGastric emptyingHypoglycemic eventsPatientsSurgeryComplicationsRisk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control.
Lipska K, Gilliam L, Lee C, Liu J, Liu V, Moffet H, Parker M, Zapata H, Karter A. Risk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control. Diabetes Care 2024, 47: 2258-2265. PMID: 39436715, PMCID: PMC11655405, DOI: 10.2337/dc24-1612.Peer-Reviewed Original ResearchRisk of hospitalizationIncreased risk of hospitalizationType 2 diabetesRelative riskIntegrated health care delivery systemGlycemic controlHealth care delivery systemCare delivery systemOlder patientsBone infectionIncreased riskRelative risk of hospitalizationEstimated incidence rateGlycemic control levelsRates of hospitalizationRetrospective cohort studySoft tissueCategories of infectionOlder adultsUnadjusted riskClinical guidelinesRisk of infectionIncidence rateCohort studyNegative binomial modelGLP1R Gene Expression and Kidney Disease Progression
Triozzi J, Yu Z, Giri A, Chen H, Wilson O, Ferolito B, Ikizler T, Akwo E, Robinson-Cohen C, Gaziano J, Cho K, Phillips L, Tao R, Pereira A, Hung A, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. GLP1R Gene Expression and Kidney Disease Progression. JAMA Network Open 2024, 7: e2440286. PMID: 39453656, PMCID: PMC11581634, DOI: 10.1001/jamanetworkopen.2024.40286.Peer-Reviewed Original ResearchConceptsGenetic association studiesKidney disease progressionRisk of kidney disease progressionVeterans Affairs Million Veteran ProgramAssociation studiesGenetic risk scoreMillion Veteran ProgramGLP-1RAsDisease progressionIncident end-stage kidney diseaseBody mass indexGlycemic controlGene expressionVeteran ProgramObesity statusMain OutcomesUnadjusted modelsGlucagon-like peptide 1 receptor agonistsStudy participantsPeptide 1 receptor agonistsAbsence of diabetesMass indexMedian Follow-UpRisk scoreGenotype-Tissue Expression projectDiet quality, community food access, and glycemic control among nulliparous individuals with diabetes
Venkatesh K, Yee L, Wu J, Joseph J, Garner J, McNeil R, Scifres C, Mercer B, Reddy U, Silver R, Saade G, Parry S, Simhan H, Post R, Walker D, Grobman W. Diet quality, community food access, and glycemic control among nulliparous individuals with diabetes. Primary Care Diabetes 2024, 18: 506-510. PMID: 38972826, PMCID: PMC12171983, DOI: 10.1016/j.pcd.2024.06.011.Peer-Reviewed Original Research70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)
HEROLD K, DAYAN C, CHATENOUD L, GITELMAN S, SUMNIK Z, SIMMONS K, SZYPOWSKA A, KNECHT L, NIEMOELLER E, TIAN W, RAMOS E. 70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D). Diabetes 2024, 73 DOI: 10.2337/db24-70-or.Peer-Reviewed Original ResearchIntent-to-treatInsulin doseFunction preservationPer-protocolIntent-to-treat populationß-cell functionAnti-CD3 mAbReduced insulin doseLower insulin doseSustained glycemic controlPP populationTeplizumabMetabolic outcomesPBO groupHbA1c levelsPP analysisGlycemic controlTreatment complianceDoseDelayed onsetRandomized participantsIncorrect treatmentInsulinWeeksTreatment1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials
BJORNSTAD P, DANNE T, TAMBORLANE W, KLINGENSMITH G, SCHUELER E, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S, LAFFEL L. 1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials. Diabetes 2024, 73 DOI: 10.2337/db24-1140-p.Peer-Reviewed Original ResearchDiabetic kidney diseaseKidney diseaseHoc AnalysisDiabetic kidney disease riskEarly diabetic kidney diseaseBaseline to weekImpact of empagliflozinCystatin C equationClinically relevant improvementNational Institute of DiabetesDigestive and Kidney DiseasesPost Hoc AnalysisEGFR changeIncreased riskHyperfiltrationPubertal statusGlycemic controlEGFRC equationLong-term effectsPotential long-term effectsRelevant improvementNormofiltrationT2DHealthy youthTAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sørensen J, Roostalu U, Vickers S, Wu S, Anacker C, Synan C, Jones P, Milanovic S, Hopkins S, Bristow L, Koblan K. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding. Molecular Metabolism 2024, 80: 101883. PMID: 38237896, PMCID: PMC10839149, DOI: 10.1016/j.molmet.2024.101883.Peer-Reviewed Original ResearchConceptsTrace amine-associated receptor 1Trace amine-associated receptor 1 agonistAntipsychotic drugsEffects of TAAR1 agonistsOlanzapine-induced weight gainDiet-induced obesityReduced body weightFood intakeHigh-fat dietSub-chronic administrationC-Fos protein expressionDiet-induced obese miceImprove glycemic controlRegulators of metabolic controlGlycemic controlGastric emptyingSchizophrenia patientsTAAR1 agonistsHedonic feedingLimbic structuresBody weightMetabolic parametersMouse modelGlucose toleranceWeight gain
2023
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results
Miller K, Bauza C, Kanapka L, Clements M, DeSalvo D, Hood K, Messer L, Sherr J, Bergamo K, Criego A, Freiner E, Lyons S, Monzavi R, Moore W, Prahalad P, Simmons J, Sulik M, Wadwa R, Weinstock R, Willi S, Williams K, Laffel L, Group F. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results. Pediatric Diabetes 2023, 2023: 6718115. PMID: 40303270, PMCID: PMC12016685, DOI: 10.1155/2023/6718115.Peer-Reviewed Original ResearchType 1 diabetesMedian percent timeUse of CGMBlood glucose monitoringYoung adultsCGM initiationExtension phaseGlucose monitoringPercent timeContinuous glucose monitoringMean hemoglobinGlycemic controlCGM groupUp ResultsClinical trialsGlycemic outcomesGlycemic benefitsCGM useMonitoring interventionsType 1Further evaluationBGM groupWeeksDlAdultsThe Effect of Salacia Reticulata Extract Biscuits on Blood Sugar Control of Type 2 Diabetes Mellitus Patients: A Two-Period, Two-Sequence, Crossover, Randomized, Triple-Blind, Placebo-Controlled, Clinical Trial
Siribaddana S, Medagama A, Wickramasinghe N, Siribaddana N, Agampodi S, Fernando D. The Effect of Salacia Reticulata Extract Biscuits on Blood Sugar Control of Type 2 Diabetes Mellitus Patients: A Two-Period, Two-Sequence, Crossover, Randomized, Triple-Blind, Placebo-Controlled, Clinical Trial. Cureus 2023, 15: e45921. PMID: 37885536, PMCID: PMC10599346, DOI: 10.7759/cureus.45921.Peer-Reviewed Original ResearchType 2 diabetesKothala-himbutuPlacebo biscuitsBiscuit groupTwo-sequenceComputer-generated random numbersTeaching Hospital AnuradhapuraMean HbA1c levelBlood sugar controlPrimary outcome measureTwo-periodHbA1c levelsMean HbA1cGlycemic stabilityGlycemic controlMellitus patientsCrossover studyWashout periodSugar controlHeart diseaseTreatment allocationClinical trialsOutcome measuresPlaceboPatientsAdolescent‐ and Young Adult‐Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial
Messer L, Bauza C, Miller K, Clements M, DeSalvo D, Sherr J, Weinstock R, Hood K, Laffel L. Adolescent‐ and Young Adult‐Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial. Pediatric Diabetes 2023, 2023: 6906023. PMID: 40303243, PMCID: PMC12016964, DOI: 10.1155/2023/6906023.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexYoung adultsBlood glucose metersAdolescents/young adultsGood glycemic controlSleep Quality IndexDays/weekType 1 diabetesContinuous glucose monitor useUse of CGMContinuous glucose monitoringBenefits of CGMGlycemic controlCGM groupClinical trialsCGM useMedical outcomesBGM groupGlucose monitoringMonitor useWeeksConfidence ScaleEmotional healthGlucose dataAdultsGlycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study
Lipska K, Huang E, Liu J, Parker M, Laiteerapong N, Grant R, Moffet H, Karter A. Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study. Journal Of The American Geriatrics Society 2023, 71: 3692-3700. PMID: 37638777, PMCID: PMC10872822, DOI: 10.1111/jgs.18565.Peer-Reviewed Original ResearchConceptsRisk of complicationsComplication riskPoor healthIntermediate healthOlder adultsGood healthRetrospective cohort studyEndocrine Society guidelinesIntegrated healthcare delivery systemType 2 diabetesProportional hazards modelHealth status categoriesHealthcare delivery systemMacrovascular eventsCohort studyGlycemic controlPrimary outcomeSevere hypoglycemiaSociety guidelinesClinical variablesInsulin secretagoguesHazards modelComplicationsCombined outcomeAging StudyEvaluation of the diabetes care cascade and compliance with WHO global coverage targets in Iran based on STEPS survey 2021
Azadnajafabad S, Ahmadi N, Rezaei N, Rashidi M, Saeedi Moghaddam S, Mohammadi E, Abbasi-Kangevari M, Naderian M, Ghasemi E, Farzi Y, Kazemi A, Dilmaghani-Marand A, Yoosefi M, Rezaei S, Nasserinejad M, Fattahi N, Rezaei N, Haghshenas R, Foroutan Mehr E, Koolaji S, Razi F, Djalalinia S, Larijani B, Farzadfar F. Evaluation of the diabetes care cascade and compliance with WHO global coverage targets in Iran based on STEPS survey 2021. Scientific Reports 2023, 13: 13528. PMID: 37598214, PMCID: PMC10439917, DOI: 10.1038/s41598-023-39433-7.Peer-Reviewed Original ResearchConceptsCare cascadeSTEPS surveyCoverage targetsDM diagnosisDiabetes care cascadeTreatment coverageSub-optimal careGlycemic controlPrevalence of DMDiabetes mellitusDiabetes awarenessNational prevalenceWorld Health OrganizationControl statusCareGood glycemic controlIranian populationPrediabetesHealth OrganizationGlobal targetsDiabetesPrevalenceSurveyPopulationCompliance222-OR: Metformin Reduces Fasting Glycemia in Well-Controlled Type 2 Diabetes by Promoting Aerobic Glycolysis Independent of Decreasing Endogenous Glucose Production
SARABHAI T, LAMOIA T, FRIESL S, JONUSCHEIT M, PETERSEN K, SHULMAN G, RODEN M. 222-OR: Metformin Reduces Fasting Glycemia in Well-Controlled Type 2 Diabetes by Promoting Aerobic Glycolysis Independent of Decreasing Endogenous Glucose Production. Diabetes 2023, 72 DOI: 10.2337/db23-222-or.Peer-Reviewed Original ResearchEndogenous glucose productionRates of EGPType 2 diabetesHepatic ATP contentMetformin treatmentGlucose clearanceNovo NordiskGlucose productionGlycogen contentGlucose-lowering effectHepatic TAG contentLactate productionBlood glucose levelsPlasma glucose concentrationPeripheral glucose clearanceHepatic glycogen contentATP contentAdvisory PanelFortress BiotechMetformin-induced inhibitionGlycemic controlDohme Corp.Hepatic triglyceridesMitochondrial electron transport chain activityGlucose levels164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost Hoc AnalysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc AnalysisIncreased prevalenceGlucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
Cooper D, Ramachandra R, Ceban F, Di Vincenzo J, Rhee T, Mansur R, Teopiz K, Gill H, Ho R, Cao B, Lui L, Jawad M, Arsenault J, Le G, Ramachandra D, Guo Z, McIntyre R. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. Journal Of Psychiatric Research 2023, 164: 80-89. PMID: 37331261, DOI: 10.1016/j.jpsychires.2023.05.041.Peer-Reviewed Original ResearchConceptsGLP-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsIncident depressionDiabetes mellitusReceptor agonistType 2 diabetes mellitusRetrospective observational studyPubMed/MEDLINEEnglish-language articlesHigh interstudy heterogeneityGoogle Scholar databasesPaucity of literatureGlycemic controlNeuroprotective effectsAntidepressant propertiesNeuroprotective potentialInterstudy heterogeneityObservational studyPatientsSystematic reviewAgonistsMellitusScholar databasesProtective factorsIn silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing
Libera A, Toffanin C, Drecogna M, Galderisi A, Pillonetto G, Cobelli C. In silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing. APL Bioengineering 2023, 7: 026105. PMID: 37229215, PMCID: PMC10205143, DOI: 10.1063/5.0145446.Peer-Reviewed Original ResearchIP insulin deliveryInsulin deliveryPeritoneal spaceMeal announcementChronic autoimmune diseaseInsulin kineticsParadigm of treatmentBeta-cell functionIntraperitoneal insulin deliveryType 1 diabetesInpatient trialPeripheral hyperinsulinemiaMacrovascular complicationsGlycemic controlTwo-compartment modelInsulin replacementAutoimmune diseasesInsulin delivery systemsInsulin secretionDaily burdenInsulin pumpAid useCell functionArtificial pancreasDiseaseReligion, spirituality and improved glycemic control among people with type 2 diabetes: A systematic review
Weber J, Doolittle B. Religion, spirituality and improved glycemic control among people with type 2 diabetes: A systematic review. The International Journal Of Psychiatry In Medicine 2023, 58: 617-636. PMID: 37164905, DOI: 10.1177/00912174231176171.Peer-Reviewed Original ResearchType 2 diabetesGlycemic controlSystematic reviewCochrane Central RegisterSearch termsControlled clinical trialsInternational Prospective RegisterEnglish-language articlesSelf-management practicesRelevant databasesCentral RegisterBlood glucoseDiabetes outcomesClinical trialsProspective RegisterNeutral associationsDiabetesLanguage articlesStudy designSmall sample sizeSociological AbstractsPatientsPositive associationAssociationSystematic literature review
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply